Molecular sub-group-specific immunophenotypic changes are associated with outcome in recurrent posterior fossa ependymoma
about
Molecular Markers in Low-Grade Glioma-Toward Tumor ReclassificationDisrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors.CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy.Serpine2/PN-1 Is Required for Proliferative Expansion of Pre-Neoplastic Lesions and Malignant Progression to Medulloblastoma.Identification of targets for rational pharmacological therapy in childhood craniopharyngioma.Pediatric Brain Tumors: Innovative Genomic Information Is Transforming the Diagnostic and Clinical Landscape.Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients.Interleukin-6/STAT3 Pathway Signaling Drives an Inflammatory Phenotype in Group A EpendymomaPrimary Glial and Neuronal Tumors of the Ovary or Peritoneum: A Clinicopathologic Study of 11 Cases.Molecular genetics of ependymomas and pediatric diffuse gliomas: a short review.Molecular biology of pediatric brain tumors and impact on novel therapies.Advances in Management of Pediatric Ependymomas.Characterization of 2 Novel Ependymoma Cell Lines With Chromosome 1q Gain Derived From Posterior Fossa Tumors of Childhood.Anaplastic Lymphoma Kinase as a Cancer Target in Pediatric Malignancies.Reduction of CD200 expression in glioma cells enhances microglia activation and tumor growth.Preoperative systemic levels of VEGFA, IL-7, IL-17A, and TNF-β delineate two distinct groups of children with brain tumors.Molecular pathology of paediatric central nervous system tumours.Aberrant immunostaining pattern of the CD24 glycoprotein in clinical samples and experimental models of pediatric medulloblastomas.Clinical, Pathological, and Molecular Characterization of Infant Medulloblastomas Treated with Sequential High-Dose Chemotherapy.NF-κB upregulation through epigenetic silencing of LDOC1 drives tumor biology and specific immunophenotype in Group A ependymoma.microRNA network analysis identifies miR-29 cluster as key regulator of LAMA2 in ependymomaSpecific expression of PD-L1 in RELA-fusion supratentorial ependymoma: Implications for PD-1-targeted therapy.A pediatric trial of radiation/cetuximab followed by irinotecan/cetuximab in newly diagnosed diffuse pontine gliomas and high-grade astrocytomas: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study.Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomasTranscriptional co-expression regulatory network analysis for Snail and Slug identifies IL1R1 , an inflammatory cytokine receptor, to be preferentially expressed in ST-EPN- RELA and PF-EPN-A molecular subgroups of intracranial ependymomas
P2860
Q28383205-B64DD8C3-99F2-48CD-82CE-EB61F4A9F045Q34553348-B5AF25AB-8F46-4DE3-9376-8D1A10DBFBA3Q34976095-9C862F55-D5C4-4641-BD11-FF9D58550C85Q35611341-8BCCD46D-3C9E-4DF9-B900-E3E5ED7F7CC6Q35627053-4D8AC818-E8CA-419F-8461-DD27DCAE38F0Q35754390-FBC67E32-1291-4F7F-A677-B53D1763580CQ35788894-0CCD52FE-4E9C-490A-B908-B4E5A38962A8Q36132647-D91FE00C-1DC7-4F21-B857-93B2246E5243Q36892843-AE54D68C-B33B-4D48-8723-CF446C81AC07Q38245575-C58617B8-6B83-4BD2-B2DF-0E31E0F6FF3FQ38359284-A2E829FD-A038-40BB-90D3-6695D330D909Q38586580-089BC422-BD79-4476-9911-B5868ADA1330Q38597697-7B673C6E-41DF-4DE3-ABF0-D0F1D7F24697Q38616826-DFFF9472-7ABC-4277-B181-CA830FA48023Q38740460-D19D34C2-59E4-4BBB-A5DD-A99A41A3AEB1Q38809641-AF8F214D-D55D-42A2-BA8B-A803949D9C0AQ38971961-DBCEBD7F-DBCD-476C-A4C2-F87837EC1636Q39023964-9F528F70-A027-42E8-8C87-20C72395C3A6Q39795085-98567A2E-FD23-41C5-AF06-626725FF4C3DQ40199358-D30C41D7-9EBE-426A-8337-FDDB160A1DB3Q42562689-EC1BB180-D20B-4A4C-A2B2-CA1805B543D5Q47852056-F5F812DA-F31C-4D63-A4DB-358EBEC007A0Q48095585-10AD8981-53C7-406D-A6BD-B9582F6A61A0Q57652291-1C406207-A0F4-4237-A4F6-ED0B825506A2Q59135007-4D4ADA3B-8718-402B-9D81-AB95695B26DB
P2860
Molecular sub-group-specific immunophenotypic changes are associated with outcome in recurrent posterior fossa ependymoma
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Molecular sub-group-specific i ...... ent posterior fossa ependymoma
@en
Molecular sub-group-specific i ...... nt posterior fossa ependymoma.
@nl
type
label
Molecular sub-group-specific i ...... ent posterior fossa ependymoma
@en
Molecular sub-group-specific i ...... nt posterior fossa ependymoma.
@nl
prefLabel
Molecular sub-group-specific i ...... ent posterior fossa ependymoma
@en
Molecular sub-group-specific i ...... nt posterior fossa ependymoma.
@nl
P2093
P2860
P1476
Molecular sub-group-specific i ...... ent posterior fossa ependymoma
@en
P2093
Andrea M Griesinger
Andrew M Donson
Arthur K Liu
Diane K Birks
Ichiro Nakachi
Lindsey M Hoffman
Michael H Handler
Michael Wang
Molly S Hemenway
Todd C Hankinson
P2860
P2888
P304
P356
10.1007/S00401-013-1212-8
P577
2013-11-17T00:00:00Z